One Drug Outfit On China's Periphery Stands Out From The Crowd Through Innovation
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - A famous ability to copy, combined with a chronic shortage of innovation, has long defined China's pharmaceutical industry
You may also be interested in...
PLx Pharm Signs First China Licensing Deal With Lee’s Pharma For GI-safe Aspirin
Lee’s Pharma looks to take on Bayer’s aspirin in China by seeking an Rx indication.
Lee's Pharmaceutical In-Licenses United Therapeutics' Pulmonary Arterial Hypertension Treatment Remodulin In China
SHANGHAI - Hong Kong-based Lee's Pharmaceutical and U.S.-based United Therapeutics signed an agreement for the distribution of United Therapeutics' pulmonary arterial hypertension treatment Remodulin (treprostinil) in China, despite a recent setback for the drug's launch in Europe
Lee's Pharmaceutical In-Licenses United Therapeutics' Pulmonary Arterial Hypertension Treatment Remodulin In China
SHANGHAI - Hong Kong-based Lee's Pharmaceutical and U.S.-based United Therapeutics signed an agreement for the distribution of United Therapeutics' pulmonary arterial hypertension treatment Remodulin (treprostinil) in China, despite a recent setback for the drug's launch in Europe